We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Centene (CNC) to Post Q3 Earnings: What's in the Cards?
Read MoreHide Full Article
Centene Corporation (CNC - Free Report) is slated to release third-quarter 2022 results on Oct 25, before the opening bell.
Q3 Estimates
The Zacks Consensus Estimate for Centene's third-quarter earnings per share is pegged at $1.22, indicating a decline of 3.2% from the prior-year quarter's reported figure.
The consensus mark for revenues stands at $35.5 billion, suggesting growth of 9.5% from the year-ago quarter’s figure. Our estimate indicates total revenues of $35.3 billion for the third quarter.
Earnings Surprise History
Centene contains a strong earnings surprise record. Its bottom line surpassed estimates in three of the trailing four quarters and missed the same once, the average surprise being 2.99%. This is depicted in the chart below:
Revenues of Centene are likely to have increased on the back of improved premium and service revenues in the third quarter. Premiums are expected to have been driven by the growing membership across CNC’s Medicaid, Medicare and Marketplace businesses that form part of its government business.
Premiums remain the most significant contributor to a health insurer’s top line. Sound performances of Centene’s government business fetched several contract wins that enabled it to foray into different U.S. regions. This, in turn, might have also strengthened its membership in the to-be-reported quarter.
The Zacks Consensus Estimate for Centene's premiums is pegged at $31.4 billion, indicating an improvement of 8.8% from the prior-year quarter’s reported figure. Our estimate for the metric is $30.7 billion.
A diversified service offering suite comprising Medicaid, Medicare, commercial programs, prescription drug plan (PDP) and correctional healthcare services is likely to have boosted service revenues of Centene in the third quarter. The consensus mark for the service revenues stands at $2.2 billion (suggesting a 33.6% surge from the year-ago quarter’s tally), while our estimate indicates the metric to be $2.8 billion.
The commercial healthcare business of Centene is likely to have gained on prudent pricing actions in the to-be-reported quarter.
In spite of several cost-cutting efforts, the bottom line of Centene is expected to have taken a hit in the third quarter. This is because of elevated operating costs stemming from higher medical costs, cost of services, and selling, general and administrative expenses.
In addition, lower investment and other income might have hampered CNC’s margins. The Zacks Consensus Estimate for investment and other income is pegged at $129 million, suggesting a 69.6% plunge from the prior-year quarter’s reading.
What Our Quantitative Model Predicts
Our proven model does not conclusively predict an earnings beat for Centene this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that's not the case here as elaborated below.
Earnings ESP: Centene has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
While earnings beat looks uncertain for Centene, there are some companies from the Medical space worth considering as our model shows that these have the right combination of elements to beat on earnings beat this time around:
Genmab A/S (GMAB - Free Report) has an Earnings ESP of +18.10% and a Zacks Rank of 2 at present. The Zacks Consensus Estimate for GMAB’s third-quarter 2022 earnings stands at 23 cents per share, indicating growth of 9.5% from the prior-year quarter’s actuals.
Genmab’s bottom line beat earnings estimates in each of the last four reported quarters.
Humana Inc. (HUM - Free Report) has an Earnings ESP of +1.12% and a Zacks Rank #2. The Zacks Consensus Estimate for HUM’s third-quarter 2022 earnings is pegged at $6.24 per share, suggesting growth of 29.2% from the prior-year quarter's reported figure.
Humana's earnings beat estimates in each of the trailing four quarters.
Haemonetics Corporation (HAE - Free Report) has an Earnings ESP of +2.16% and a Zacks Rank of 3. The Zacks Consensus Estimate for HAE’s third-quarter 2022 earnings is pegged at 70 cents per share, indicating an improvement of 16.7% from the year-ago quarter's reported figure.
Haemonetics’ earnings beat estimates in three of the trailing four quarters and missed the mark once.
Image: Shutterstock
Centene (CNC) to Post Q3 Earnings: What's in the Cards?
Centene Corporation (CNC - Free Report) is slated to release third-quarter 2022 results on Oct 25, before the opening bell.
Q3 Estimates
The Zacks Consensus Estimate for Centene's third-quarter earnings per share is pegged at $1.22, indicating a decline of 3.2% from the prior-year quarter's reported figure.
The consensus mark for revenues stands at $35.5 billion, suggesting growth of 9.5% from the year-ago quarter’s figure. Our estimate indicates total revenues of $35.3 billion for the third quarter.
Earnings Surprise History
Centene contains a strong earnings surprise record. Its bottom line surpassed estimates in three of the trailing four quarters and missed the same once, the average surprise being 2.99%. This is depicted in the chart below:
Centene Corporation Price and EPS Surprise
Centene Corporation price-eps-surprise | Centene Corporation Quote
Factors to Note
Revenues of Centene are likely to have increased on the back of improved premium and service revenues in the third quarter. Premiums are expected to have been driven by the growing membership across CNC’s Medicaid, Medicare and Marketplace businesses that form part of its government business.
Premiums remain the most significant contributor to a health insurer’s top line. Sound performances of Centene’s government business fetched several contract wins that enabled it to foray into different U.S. regions. This, in turn, might have also strengthened its membership in the to-be-reported quarter.
The Zacks Consensus Estimate for Centene's premiums is pegged at $31.4 billion, indicating an improvement of 8.8% from the prior-year quarter’s reported figure. Our estimate for the metric is $30.7 billion.
A diversified service offering suite comprising Medicaid, Medicare, commercial programs, prescription drug plan (PDP) and correctional healthcare services is likely to have boosted service revenues of Centene in the third quarter. The consensus mark for the service revenues stands at $2.2 billion (suggesting a 33.6% surge from the year-ago quarter’s tally), while our estimate indicates the metric to be $2.8 billion.
The commercial healthcare business of Centene is likely to have gained on prudent pricing actions in the to-be-reported quarter.
In spite of several cost-cutting efforts, the bottom line of Centene is expected to have taken a hit in the third quarter. This is because of elevated operating costs stemming from higher medical costs, cost of services, and selling, general and administrative expenses.
In addition, lower investment and other income might have hampered CNC’s margins. The Zacks Consensus Estimate for investment and other income is pegged at $129 million, suggesting a 69.6% plunge from the prior-year quarter’s reading.
What Our Quantitative Model Predicts
Our proven model does not conclusively predict an earnings beat for Centene this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that's not the case here as elaborated below.
Earnings ESP: Centene has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Centene currently carries a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here.
Stocks to Consider
While earnings beat looks uncertain for Centene, there are some companies from the Medical space worth considering as our model shows that these have the right combination of elements to beat on earnings beat this time around:
Genmab A/S (GMAB - Free Report) has an Earnings ESP of +18.10% and a Zacks Rank of 2 at present. The Zacks Consensus Estimate for GMAB’s third-quarter 2022 earnings stands at 23 cents per share, indicating growth of 9.5% from the prior-year quarter’s actuals.
Genmab’s bottom line beat earnings estimates in each of the last four reported quarters.
Humana Inc. (HUM - Free Report) has an Earnings ESP of +1.12% and a Zacks Rank #2. The Zacks Consensus Estimate for HUM’s third-quarter 2022 earnings is pegged at $6.24 per share, suggesting growth of 29.2% from the prior-year quarter's reported figure.
Humana's earnings beat estimates in each of the trailing four quarters.
Haemonetics Corporation (HAE - Free Report) has an Earnings ESP of +2.16% and a Zacks Rank of 3. The Zacks Consensus Estimate for HAE’s third-quarter 2022 earnings is pegged at 70 cents per share, indicating an improvement of 16.7% from the year-ago quarter's reported figure.
Haemonetics’ earnings beat estimates in three of the trailing four quarters and missed the mark once.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.